Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial

There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine

This daunting challenge is not only for India but also for all the governments across the globe as they start inoculating their populations to tackle the pandemic, noted Dr Soumya Swaminathan, Chief Scientist of WHO

The statement came shortly after Adar Poonawala, CEO, Serum Institute tweeted that a public statement would be issued to clear up any miscommunication between the two companies

COVID-19 vaccine update: India has approved two coronavirus vaccines for emergency use - Bharat Biotech-ICMR's Covaxin and Covishield manufactured by Pune's Serum Institute

Coronavirus vaccine in India: Adar Poonawalla, CEO of Serum Institute of India that is manufacturing Covishield had said that the company is ready to roll out its vaccine in the coming weeks

Bitcoin crosses $34,000 first time in 12 years, rises $5,000 in 3 days Bitcoin continued its unabated rally on the third day of 2021. The most popular cryptocurrency surged past $34,000 on Sunday, the day of Bitcoin Network's 12-year anniversary. The development came within 24 hours of Bitcoin crossing the $30,000 milestone. Bitcoin's continuous surge during the past three days comes in the backdrop of a historic year when the digital currency gave more than 300 per cent returns. 'Congrat...

The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults

Calling it a great day for the country, AIIMS Director Dr Randeep Guleria said that initially Serum-AstraZeneca's Covishield will be administered to the people

Two leading vaccine contenders in India have been granted approval for restricted use in the country. Check out how netizens reacted to the news of the vaccines getting approved

Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November

The last few decades saw MNCs from abroad do business and prosper in India but this decade will belong to the Indian MNCs, he said, after laying the foundation stone for the permanent campus of IIM-Sambalpur in Odisha through video conference

The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter

A sample number of beneficiaries will undergo a mock immunisation process. Staff of vaccination centres, a select group of healthcare workers will participate in the mock immunisation drive

Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation

This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use

Russia's Gamaleya centre had earlier invited researchers from the University of Oxford to add a component of its vaccine to a component of AstraZeneca's, informed Alexander Gintsburg, Gamaleya centre's head

The vaccine development process by Bharat Biotech, Biological E Ltd and Aurobindo Pharma are currently in various stages, while Dr Reddy's and Hetero have tie ups for manufacturing the vaccine

COVID-19 vaccination drive: The mock drill will be like the actual vaccination drive but there will be no vaccine administration. Data will be fed to the Co-WIN app, cold storage will be tested and vaccine transportation from cold storage to the sites, crowd management etc will be checked

Tthe researchers in the Storm Chase study believe a Long-Acting AntiBody (LAAB) known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to coronavirus